Corvus Pharmaceuticals Inc
F:C17
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Corvus Pharmaceuticals Inc
F:C17
|
US |
|
Valuence Merger Corp I
NASDAQ:VMCA
|
US |
|
P
|
Purple Biotech Ltd
TASE:PPBT
|
IL |
|
I
|
Ice Fish Farm AS
F:4YYA
|
NO |
|
Etablissements Maurel et Prom SA
OTC:EBLMY
|
FR |
|
L
|
Liberty Defense Holdings Ltd
OTC:LDDFF
|
CA |
|
D
|
Digital Media Solutions Inc
OTC:DMSL
|
US |
|
R
|
Reflex Advanced Materials Corp
F:HF2
|
CA |
|
W
|
Winpak Ltd
F:25W
|
CA |
|
E
|
Eureking SA
PAR:KINGS
|
FR |
|
M
|
Marie Brizard Wine and Spirits SA
F:BED
|
FR |
|
Otello Corporation ASA
OSE:OTEC
|
NO |
|
S
|
Shadman Cotton Mills Ltd
KAR:SHCM
|
PK |
|
Lithium Chile Inc
F:KC3
|
CA |
|
B
|
BrooqLy Inc
OTC:BRQL
|
US |
|
Safe SA
F:OR9
|
FR |
|
S
|
Standard BioTools Inc
SWB:FLB
|
US |
Discount Rate
C17 Cost of Equity
Discount Rate
C17's Cost of Equity, calculated using the formula Risk-Free Rate + Beta x ERP, stands at 9.57%. The Beta, indicating the stock's volatility relative to the market, is 1.11, while the current Risk-Free Rate, based on government bond yields, is 4.8%, and the ERP, measuring the extra return over the risk-free rate required by investors, is 4.3%.
C17 WACC
Discount Rate
C17's Weighted Average Cost of Capital (WACC) is calculated as the weighted average of its cost of equity and cost of debt, adjusted for tax. The WACC stands at 9.57%. This includes the cost of equity at 9.57%, calculated as Risk-Free Rate + Beta x ERP, and the cost of debt at 9.05%, reflecting the interest rate on C17's debt adjusted for tax benefits. The weight of debt in the capital structure is 0%.
What is C17's discount rate?
C17's current Cost of Equity is 9.57%, while its WACC stands at 9.57%. The selection of the appropriate discount rate is contingent on the type of cash flows being discounted.
For Equity Valuation: When valuing equity, especially in scenarios where you are discounting cash flows to equity holders (such as Net Income, Earnings Per Share (EPS), or Free Cash Flow to Equity), the Cost of Equity should be used.
For Firm Valuation: In contrast, when valuing the entire firm and discounting cash flows available to both debt and equity holders (like Free Cash Flow to the Firm), the Weighted Average Cost of Capital (WACC) is the appropriate rate.
How is Cost of Equity for C17 calculated?
The Cost of Equity represents the return a company must offer investors to compensate for the risk of investing in its stock. It's calculated using the Capital Asset Pricing Model (CAPM), which combines the risk-free rate, the stock's beta, and the equity risk premium (ERP).
This model considers the inherent risk of investing in the stock compared to a risk-free investment and the market's overall risk.
Here is how we calculate the cost of equity for
C17
How is WACC for C17 calculated?
WACC, or Weighted Average Cost of Capital, is a calculation that reflects the average rate of return a company is expected to pay its security holders to finance its assets. It is a critical measure in financial analysis for valuing a company’s entire operations.
The WACC formula combines the costs of equity and debt, weighted by their respective proportions in the company's capital structure.
Here is how we calculate WACC for
C17
